Early (or late?) to the starting gate

Despite a whipsaw market, three bravehearts are attempting to sell IPOs. The list includes diagnostic developer Biosite Diagnostics; Coulter Pharmaceutical, a developer of lymphoma therapies; and Epix Medical Inc. (formerly Metasyn), a developer of imaging agents. If sold as proposed, the companies would carve $74 million out of the funding pie. The companies may be hoping that fund managers will be looking for new opportunities when the whistle blows in January.

MARKET HOPEFULS: Biosite Diagnostics Inc. (Proposed:BSTE) filed to sell 2 million shares at $11-$13. A $12 price would value the company at $143 million. The

Read the full 962 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE